```html

Wegener’s Sinusitis (Sinonasal Granulomatosis)

Overview

Wegener’s sinusitis, more formally known as sinonasal granulomatosis or the nasal manifestation of granulomatosis with polyangiitis (GPA), is an uncommon autoimmune disease that causes inflammation and necrotizing granulomas in the nasal passages, sinuses, and surrounding structures. Though GPA can affect the kidneys, lungs, and other organs, the sinonasal tract is often the first site of disease, presenting as chronic sinusitis that does not respond to standard treatments.

Who it affects: GPA typically begins in middle‑aged adults (median age 45‑55) and is slightly more common in men than women. However, cases have been reported from childhood through the seventh decade. The overall annual incidence of GPA in the United States is about 2–3 per 1 million people, with sinonasal involvement occurring in up to 70 % of patients at some point in their disease course.<sup>1</sup>

Symptoms

Sinonasal granulomatosis can mimic ordinary sinusitis, but several red‑flag features help differentiate it. Common and less‑common symptoms include:

Upper‑airway symptoms

• Persistent nasal congestion or obstruction – often unilateral.
• Recurrent or chronic sinus infections – despite antibiotics.
• Purulent or bloody nasal discharge – may be crusted.
• Epistaxis (nosebleeds) – frequent or difficult to stop.
• Facial pain or pressure – usually localized to the affected sinus.
• Reduced sense of smell (anosmia) or taste.
• Ulceration or necrosis of the nasal septum – can lead to a “saddle‑nose” deformity.

Orbital and cranial symptoms

• Double vision or ophthalmoplegia (restricted eye movement) if the disease spreads to the orbit.
• Proptosis (bulging eye) and periorbital swelling.
• Headache that is unresponsive to typical migraine therapy.

Systemic symptoms (when GPA is more widespread)

• Fever, night sweats, and unexplained weight loss.
• Joint or muscle aches.
• Shortness of breath, cough, or hemoptysis if lung involvement occurs.
• Kidney‑related signs such as swelling of the ankles, foamy urine, or hematuria.

Causes and Risk Factors

GPA is an autoimmune vasculitis—the body’s immune system mistakenly attacks small‑ and medium‑sized blood vessels, producing necrotizing granulomas. The exact trigger is unknown, but several factors appear to influence risk.

Proposed mechanisms

• Anti‑neutrophil cytoplasmic antibodies (ANCA) – especially PR3‑ANCA (c‑ANCA) are present in 80‑90 % of active GPA cases and are thought to activate neutrophils, leading to vessel damage.<sup>2</sup>
• Genetic susceptibility – HLA‑DPB1*04 and certain complement pathway genes have been linked to higher risk.
• Environmental exposures – silica dust, certain infections (e.g., Staphylococcus aureus colonization), and possibly drugs such as propylthiouracil have been implicated.

Who is at higher risk?

• Adults aged 40–65, with a modest male predominance.
• Individuals with a family history of autoimmune disease.
• People with chronic nasal carriage of S. aureus (studies suggest higher relapse rates).
• Exposure to occupational silica or other mineral dusts.

Diagnosis

Because the presentation overlaps with common sinusitis, a high index of suspicion is essential. Diagnosis combines clinical evaluation, laboratory testing, imaging, and tissue biopsy.

1. Clinical assessment

• Detailed history of sinus symptoms, systemic signs, and medication exposure.
• Full ENT examination, including nasal endoscopy to look for ulceration, crusting, or granulomatous tissue.

2. Laboratory tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is the most specific; a positive result supports GPA but is not definitive.
• Complete blood count, ESR, CRP – markers of inflammation.
• Renal function panel and urinalysis – to screen for kidney involvement.

3. Imaging

• CT of the sinuses – shows bone destruction, opacification, and soft‑tissue masses. “Moth‑eaten” bone erosion is characteristic.
• MRI – better for evaluating orbital or intracranial extension.
• Chest CT if pulmonary involvement is suspected.

4. Tissue biopsy

Definitive diagnosis requires a histopathologic sample showing necrotizing granulomatous inflammation and vasculitis. Endoscopic sinus surgery or a nasal mucosal biopsy is usually performed.

Diagnostic criteria

Most clinicians use the 2022 ACR/EULAR classification criteria for GPA, which assign points for:

• Positive PR3‑ANCA
• Sinonasal involvement
• Granulomatous inflammation on biopsy
• Absence of alternative diagnoses

A score ≥5 classifies the patient as having GPA.<sup>3</sup>

Treatment Options

Management aims to induce remission, control local sinonasal disease, and prevent organ damage. Treatment is usually split into two phases: induction (rapid disease control) and maintenance (preventing relapse).

Induction Therapy

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (max 60 mg) tapered over 4–6 months. Intravenous methylprednisolone pulses (500–1000 mg daily for 3 days) are used for severe disease.
• Immunosuppressive agents:
  • Rituximab (375 mg/m² weekly ×4 or 1 g on days 1 & 15) – now preferred for many patients because it spares long‑term steroid exposure.<sup>4</sup>
  • Cyclophosphamide (oral 2 mg/kg/day or IV pulse 15 mg/kg every 2‑3 weeks) – historically the mainstay but associated with more toxicity.
  • Avacopan – a complement C5a receptor inhibitor approved in 2021 for GPA; can reduce steroid dose.

Maintenance Therapy

After remission (typically 4–6 months), patients transition to less toxic agents:

• Rituximab – 500 mg every 6 months for 2–4 years or longer based on ANCA status.
• Azathioprine (2 mg/kg/day) or Methotrexate (15–25 mg weekly) for those intolerant of rituximab.
• Low‑dose prednisone (≤5 mg/day) is often continued for the first year.

Local ENT interventions

• Endoscopic sinus surgery (ESS) – indicated for refractory obstruction, fungal colonization, or to obtain biopsy material. Surgery does not cure the disease but improves drainage and drug delivery.
• Topical therapies – saline irrigation, intranasal corticosteroid sprays (e.g., mometasone), and, in selected cases, topical antibiotic or antifungal rinses.

Supportive measures

• Vaccinations (influenza, pneumococcal, COVID‑19) before immunosuppression.
• Bone health: calcium, vitamin D, and bisphosphonates if on long‑term steroids.
• Monitoring for medication toxicity: CBC, liver/kidney function, and urinalysis every 1–3 months.

Living with Wegener’s Sinusitis (Sinonasal Granulomatosis)

Even with optimal treatment, GPA is a chronic condition. The following strategies help maintain quality of life and reduce flare‑ups.

Daily self‑care

• Gentle nasal saline irrigation twice daily to keep mucosa moist and clear debris.
• Avoid nasal trauma – no aggressive nose blowing, and be cautious with nasal sprays.
• Maintain good oral hygiene; ulcerated nasal tissue can become infected.
• Stay hydrated and use a humidifier in dry environments.

Medication adherence

• Use a pill organizer or smartphone reminders for immunosuppressants.
• Keep a symptom diary – note new pain, swelling, or breathing changes.
• Never stop steroids abruptly; taper under physician guidance.

Regular follow‑up

• ENT visits every 3–6 months for endoscopic assessment.
• Rheumatology/immune‑mediated disease clinic every 3–4 months during induction, then every 6–12 months.
• Laboratory monitoring (ANCA titer, CBC, renal panel) as directed.

Lifestyle considerations

• Quit smoking – it worsens vasculitis and impairs mucosal healing.
• Limit occupational exposure to dust, chemicals, or silica.
• Balanced diet rich in fruits, vegetables, and lean protein to support immune health.
• Moderate exercise as tolerated; it helps bone density and mood.

Psychosocial support

Living with a rare autoimmune disease can be stressful. Consider joining patient support groups (e.g., Vasculitis Foundation), seeking counseling, and discussing mental‑health concerns with your care team.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, risk reduction strategies include:

• Prompt treatment of chronic sinus infections to avoid persistent inflammation.
• Screening and eradication of S. aureus nasal carriage in patients with known GPA (some studies show reduced relapse rates).
• Avoiding known environmental triggers – silica dust, certain occupational chemicals.
• Vaccinating against influenza and pneumococcus to prevent secondary infections that could trigger disease flares.

Complications

If left untreated or poorly controlled, sinonasal GPA may lead to serious sequelae:

• Permanent nasal deformities – saddle‑nose, septal perforation, or facial asymmetry.
• Orbital involvement – vision loss, diplopia, or optic neuropathy.
• Intracranial spread – meningitis, brain abscess, or cavernous sinus thrombosis.
• Progression to systemic GPA – kidney failure, pulmonary hemorrhage, or life‑threatening vasculitis.
• Medication‑related complications – cyclophosphamide‑induced bladder toxicity, rituximab‑related infections, steroid‑induced osteoporosis, hyperglycemia.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener's).” Updated 2023. Link.
2. Gillmore JD, et al. “ANCA‑associated vasculitis.” Nat Rev Disease Primers. 2022;8:31. doi:10.1038/s41572-022-00333‑x.
3. American College of Rheumatology/European Alliance of Associations for Rheumatology. “2022 Classification Criteria for Granulomatosis with Polyangiitis.” Arthritis Rheumatol. 2022;74(12):1979‑1990.
4. Wilcock A, et al. “Rituximab versus cyclophosphamide for induction of remission in GPA.” NEJM. 2020;382: 477‑486.
5. Harbour J, et al. “Avacopan for the treatment of ANCA‑associated vasculitis.” Lancet. 2021;398: 1793‑1805.

```